In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors

Progress in Experimental Tumor Research

Volumn 36, Issue , 1999, Pages 143-161

  Sorrentino, B P ^a   Allay, J A ^a   Blakley, R L ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE;

CELL SEPARATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; METHODOLOGY; PHYSIOLOGY; RETROVIRUS; REVIEW;

CELL SEPARATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; RETROVIRIDAE; TETRAHYDROFOLATE DEHYDROGENASE; TRANSDUCTION, GENETIC;

EID: 0032604290     PISSN: 00796263     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061994     Document Type: Article

References (47)

1. Buckley RH, Schiff SE, Schiff RI, Roberts JL, Markert ML, Peters W, Williams LW, Ward FE: Haploidentical bone marrow stem cell transplantation in human severe combined immunodeficiency. Semin Hematol 1993;30:92.
2. Sorrentino BP, Nienhuis AW: The hematopoietic system as a target for gene therapy; in Friedmann T (ed): The Development of Gene Therapy. New York, Cold Spring Harbor Laboratory Press, in press.
3. Taylor N, Uribe L, Smith S, Jahn T, Kohn DB, Weinberg K: Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c gene. Blood 1996;87:3103.
4. Candotti F, Oakes SA, Johnston JA, Notarangelo LD, O'Shea JJ, Blaese RM: In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med 1996;183:2687.
5. Candotti F, Johnston JA, Puck JM, Sugamura K, O'Shea JJ, Blaese RM: Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood 1996;87:3097.
6. Mardiney M, Jackson SH, Spratt SK, Li F, Holland SM, Malech HL: Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. Blood 1997; 89:2268.
7. Bjorgvinsdottir H, Ding C, Pech N, Gifford MA, Li LL, Dinauer MC: Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood 1997;89:41.
8. Bunting KD, Sangster MY, Ihle JN, Sorrentino BP: Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med 1998;4:58.
9. Dick JE, Magli MC, Huszar D, Phillips RA, Bernstein A: Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 1985;42:71.
10. Eglitis MA, Kantoff P, Gilboa E, Anderson WE: Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science 1985;230:1395.
11. Keller G, Paige C, Gilboa E, Wagner EF: Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors. Nature (Lond) 1985;318:149.
12. Van Beusechem VW, Valerio D: Gene transfer into hematopoietic stem cells of nonhuman primates. Hum Gene Ther 1996;7:1649.
13. Dunbar CE, Cottier-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, et al: Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85:3048.
14. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN: Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993;342:1134.
15. Hanania EG, Giles RE, Kavanagh J, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Deisseroth AM, et al: Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 1996;93:15346.
16. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett TD, Fetell M, Reiss R, Bank A, Antman K: Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998;16:165.
17. Orlic D, Girard LJ, Jordan CT, Anderson SM, Cline AP, Bodine DM: The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. Proc Natl Acad Sci USA 1996;93: 11097.
18. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239.
19. + cells in ADA-deficient SCID neonates. Nat Med 1998;4:775.
20. Sorrentino BP: Drug resistance gene therapy; in Brenner MK, Moen RC (eds): Gene Therapy in Cancer. New York, Marcel Dekker, 1996, p 189.
21. Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis AW: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257:99.
22. Podda S, Ward M, Himelstein A, Richardson C, de la Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 1992;89:9676.
23. Allay JA, Davis BM, Gerson SL: Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp Hematol 1997;25: 1069.
24. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1997; 57:5093.
25. Simonsen CC, Levinson AD: Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA 1983;80:2495.
26. Blakley RL, Sorrentino BP: In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: Potential for clinical application. Hum Mutat 1998;11:259.
27. Spencer HT, Sleep SE, Rehg JE, Blakley RL, Sorrentino BP: A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 1996;87:2579.
28. Pawliuk R, Kay R, Lansdorp P, Humphries RK: Selection of retrovirally transduced hemotopoietic cells using CD24 as a marker of gene transfer. Blood 1994;84:2868.
29. Persons DA, Allay JA, Riberdy JM, Wersto RP, Donahue RE, Sorrentino BP, Nienhuis AW: Utilization of the green fluorescent protein gene as a marker to identify and track genetically-modified hemotopoietic cells. Nat Med 1998;4:1201.
30. Blau CA, Neff T, Papayannopoulou T: The hematological effects of folate analogs: Implications for using the dihydrofolate reductase gene for in vivo selection. Hum Gene Ther 1996;7: 2069.
31. Belt JA, Marina NM, Phelps DA, Crawford CR: Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul 1993;33:235.
32. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakley RL, Sorrentino BP: Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 1997; 90:3546.
33. Cass CE: Nucleoside transport; in Georgopapadakou NH (ed): Drug Transport in Antimicrobial Therapy and Anticancer Therapy. New York, Marcel Dekker, 1995, p 403.
34. Allay JA, Galipeau J, Blakley RL, Sorrentino BP: Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells 1998; 16(suppl 1):223.
35. Kolassa N, Jakobs ES, Buzzell GR, Paterson AR: Manipulation of toxicity and tissue distribution of tubercidin in mice by nitrobenzylthioinosine 5′-monophosphate. Biochem Pharmacol 1982;31: 1863.
36. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988;85:4486.
37. Hawley RG, Lieu FH, Fong AZ, Hawley TS: Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994; 1:136.
38. Chalfie M, Tu Y, Euskirchen G, Ward WW, Prasher DC: Green fluorescent protein as a marker for gene expression. Science 1994;263:802.
39. Persons DA, Allay JA, Allay ER, Smeyne RJ, Ashmun RA, Sorrentino BP, Nienhuis AW: Retroviralmediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 1997;90:1777.
40. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL, Sorrentino BP: In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998;4:1136.
41. Corey CA, DeSilva AD, Holland CA, Williams DA: Serial transplantation of methotrexate-resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 1990;75:337.
42. Rongen GA, Smits P, Ver Donck K, Willemsen JJ, De Abreu RA, Van Belle H, Thien T: Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. J Clin Invest 1995;95:658.
43. Beck-Engeser G, Stocking C, Just U, Albritton L, Dexter M, Spooncer E, Ostertag W: Retroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and precursor cell lines, but retroviral infection is reduced in more primitive cells. Hum Gene Ther 1991;2:61.
44. Patel M, Sleep SE, Lewis WS, Spencer HT, Mareya SM, Sorrentino BP, Blakley RL: Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants. Hum Gene Ther 1997;8:2069.
45. Tisdale JF, Hanazono Y, Sellers SE, Agricola BA, Metzger ME, Donahue RE, Dunbar CE: Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998;92:1131.
46. Kiem HP, Andrews RG, Morris JA, Peterson L, Heyward S, Allen JM, Rasko JE, Potter J, Miller AD: Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 1998;92:1878.
47. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, Leitman SF, Carter CS, Butz RE, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Gallin JI: Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997;94:12133.